* Revolade endorsed by European Medicines Agency
* Will compete with Amgen's already-approved Nplate
(Adds details on drug and competition)
LONDON, Dec 18 GlaxoSmithKline's (GSK.L) drug
Revolade has been recommended for approval in Europe to treat a
rare clotting disorder that can cause dangerous bleeding, the
European Medicines Agency said on Friday.
The drug helps stimulate bone marrow into producing blood
platelets in patients with chronic immune thrombocytopenic
ITP occurs when the immune system destroys platelet cells
that help the blood clot and low platelet levels can trigger
life-threatening bleeding. Patients with the condition are also
more likely to experience bruising.
Glaxo's oral drug, which is also known as Promacta and is
already approved in the United States, will compete with Amgen's
(AMGN.O) injectable product Nplate, which won full European
approval in February.
Analysts expect Glaxo's medicine to generate worldwide sales
of $260 million in 2012, according to consensus forecasts from
Recommendations for marketing approval by the EU drug
agency's Committee for Medicinal Products for Human Use (CHMP)
are normally endorsed by the European Commission within a couple
Revolade was discovered as a result of a research
collaboration between Glaxo and Ligand Pharmaceuticals (LGND.O).
(Reporting by Ben Hirschler; Editing by Greg Mahlich)